Los Angeles Convention Center
Los Angeles, CA
May 16-20, 2023

SeQure Dx    

We manage off-target gene editing risk for biopharma

Invaluable gene editing off-target insights from initial research to patient therapies:

Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.

Brands: NoteSeQ; ScopeSeQ; GUIDE-SeQ; ONE-seq

 Press Releases

  • SeQure Dx, a leading genomics intelligence company, is presenting at the 2023 American Society of Gene and Cell Therapy Annual Meeting Startup Spotlight at 12:50PM, today May 17th. SeQure Dx is dedicated to the advancement of on-target gene editing and cell therapies from discovery to patient.  SeQure’s preclinical platforms for the biopharma industry, NoteSeQ and ScopeSeQ, comprise a suite of proprietary, best-in-class diagnostic assays and bioinformatic analytics that span the spectrum of off-target nomination and confirmation.  The NoteSeQ and ScopeSeQ platforms comprehensively solve our partners’ preclinical off-target evaluation needs, including guide selection and Investigational New Drug submissions. SeQure Dx’s goal is to ensure that gene editing and cell therapies are suitable for all patients, who would benefit from this next generation of life-saving technologies.  For more information, please visit us at Booth 569 or at www.sequre-dx.com.